Clinical trial
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
NCT03981796 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
- Lead sponsor
- Tesaro, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- July 18, 2019
- Completion date
- November 26, 2026
- Enrollment
- 785 (actual)
- Sites
- 169
Conditions
As the registry lists them; a condition with its own page is linked.